Cel Sci (CVM) Income from Continuing Operations (2010 - 2026)
Cel Sci (CVM) posted Income from Continuing Operations of 12954009.0 for Q1 2026, down 134.11% sequentially from 5533359.0 in Q4 2025, and down 97.11% YoY from 447615269.49 in Q1 2025.
Cel Sci (CVM) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cel Sci has reported Income from Continuing Operations for 17 years, with the latest figure at 12954009.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 97.11% year-over-year to 12954009.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 41631939.0 (down 6.86% YoY) and the FY2025 annual result came in at 90717736.0, down 2.09% from the prior year.
- Income from Continuing Operations retreated to 12954009.0 in Q1 2026 per CVM's latest filing, from 5533359.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5533359.0 in Q4 2025 and troughed at 27757859.0 in Q1 2022.
- A 5-year average of 14633500.71 and a median of 12954009.0 in 2026 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations plunged 154.62% in 2023, then surged 67.46% in 2025.
- Over 5 years, Income from Continuing Operations stood at 7950549.0 in 2022, then plunged by 154.62% to 20243887.0 in 2023, then soared by 64.92% to 7101153.0 in 2024, then climbed by 22.08% to 5533359.0 in 2025, then sank by 134.11% to 12954009.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 12954009.0, 5533359.0, and 7924688.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.95 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -7.92 Mn |
| Jun 30, 2025 | -15.22 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -7.10 Mn |
| Sep 30, 2024 | -6.16 Mn |
| Jun 30, 2024 | -19.13 Mn |
| Mar 31, 2024 | -20.20 Mn |
| Dec 31, 2023 | -20.24 Mn |
| Sep 30, 2023 | -8.08 Mn |
| Jun 30, 2023 | -23.25 Mn |
| Mar 31, 2023 | -23.89 Mn |
| Dec 31, 2022 | -7.95 Mn |
| Sep 30, 2022 | -10.48 Mn |
| Jun 30, 2022 | -26.34 Mn |
| Mar 31, 2022 | -27.76 Mn |
| Dec 31, 2021 | -9.13 Mn |
| Sep 30, 2021 | -8.60 Mn |
| Jun 30, 2021 | -10.48 Mn |